The potential diagnosis role of TP53 mutation in advanced bladder cancer: A meta‐analysis

Liao, Yihao; Tang, Huiqin; Wang, Miaomiao; Wang, Keke; Jiang, Ning

doi:10.1002/jcla.23765

Cited by 10 publications

(13 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, p53 was overexpressed in urothelial carcinoma and its levels were higher in high-stage, high-grade, muscle-invasive, and metastatic disease. Those results are consistent with the recent meta-analysis published by Liao et al and reports regarding the prognostic value of p53 in NMIBC [ 31 , 32 ]. TP53 mutation is more frequent in muscle-invasive tumors when compared to non-invasive tumors (35 vs 70%), and correlates with tumor grade, stage, and disease recurrence [ 33 – 35 ].…”

Section: Discussionsupporting

confidence: 94%

The prognostic role of p53 and its correlation with CDK9 in urothelial carcinoma

et al. 2022

View full text Add to dashboard Cite

Purpose The mutation of p53 is considered a pivotal step in bladder cancer pathogenesis. Recently, distinct interactions between p53 and CDK9, a transcription regulator, have been described. In this work, we explored the prognostic role of p53 expression and evaluated its associations with CDK9 in urothelial carcinoma. Materials and methods The research group consisted of 67 bladder cancer samples and 32 normal urothelial mucosa samples. All specimens were analyzed using ImageJ and the IHC profiler plugin. To validate the results, 406 cases from The Cancer Genome Atlas database were analyzed. Results P53 and CDK9 are overexpressed in urothelial cancer tissues when compared to normal urothelial tissues (p < 0.05). High p53 expression was observed in metastatic tumors and tumors with high CDK9 expression (p < 0,05). High p53 expression was predictive for shorter survival in patients with non-muscle-invasive bladder cancer (HR = 0.107 [0.012–0.96]; p = 0.046) but did not correlate with prognosis in the muscle-invasive group. In high CDK9 cancers, high p53 expression correlated with the occurrence of high-grade and muscle-invasive tumors (p < 0.05). Conclusion High expression of p53 correlates with unfavorable clinical features of bladder cancer. CDK9 is associated with the expression of p53, possibly through interactions with p53 inhibitors. Since the blockade of CDK9 in other malignancies reactivates wild-p53 activity, confirming the crosstalk between p53 and CDK9 in bladder cancer may be another step to explain the mechanism of tumor progression in its early stages.

show abstract

Section: Discussionsupporting

confidence: 94%

The prognostic role of p53 and its correlation with CDK9 in urothelial carcinoma

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The above ndings matched those ofLiao et al, 2021 who that high stage of BC has obviously higher level of TP53 mutation than the lower stage and also consistent with those ofShao et al, 2021 who reported that TP53 mutations were most frequent among BC patients with high tumor grade. The overall analysis provides a strong support to the initial ndings, which further con rmed the potential diagnosis role of TP53 mutation in advanced BC.The occurrence or recurrence of BC is a molecular biological change or process that is effected by occupational factors, non-occupational factors, genomics and proteomics factors(Fan, et al, 2021).The value of TP53 in bladder cancer as a predictive marker of tumor recurrence and treatment selection is still in debate(Sobhani et al, 2021).…”

supporting

confidence: 88%

“…It has been reported that various cell cycle modulators, such as TP53 was frequently deregulated in BC and the tumor protein p53 (TP53) was recognized as a tumor suppressor factor for several common tumors (Liao et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

“…TP53 was recognized as a tumor suppressor gene for several common tumors, it is located on the short arm of chromosome 17p13 and it was rst discovered in 1979 (Eccles & Phipps, 2012). The mutation of TP53 was frequently observed in lots of BC patients, and TP53 mutation might cause the progress of BC because TP53 and TP53 related pathways regulated many important carcinogenesis-related signal pathways (Liao et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

TP53 Mutation for Prediction of Tumor Recurrence and Metastasis in Bladder Cancer Patients

Mamdouh

Khorshed

Aboushousha

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Bladder cancer (BC) is one of the most commonly diagnosed malignancies worldwide. Its complex etiopathogenesis is dependent on numerous risk factors that can be divided into three distinct categories: genetic and molecular abnormalities, chemical or environmental exposure and previous genitourinary disorders and family history of different malignancies. This study highlights the genetic and molecular abnormalities that considered to be part of bladder carcinogenesis such as genetic mutations of TP53.To date, cystoscopy remains the gold standard for diagnosis, butit is invasive and uncomfortable. Hence, many efforts are focusing on the development of accuratenon-invasive diagnostic tests for BC, consequently, this study aims to develop a new non-invasive and reliable test to accurately detect TP53 mutations in urine sediments of Egyptian BC patients and to evaluate the influence of their genetic status on tumor metastasis and recurrence as they are the main problems during the disease.Methods: A total of 150 BC patients and 50 healthy volunteers as controls were enrolled in this study, urine samples were obtained from all participants. DNA was extracted and TP53 mutations were examinedin exons (2+3), 4 and 5 by polymerase chain reaction (PCR). All PCR products were subjected to bidirectional sequencing.Results: Fifty four (36.0%) patients of 150 were mutated in exon (2+3) with statistically higher significant in patients when compared to controls (P = 0.001),while 96 patients(64.0%) in Exon 4, and 111 patients(74.0%) in Exon 5 with the same (P = 0.001).Moreover, a significant association was observed between TP53 status with tumor stage and grade, being alterations more common in high-stage and high-grade tumors.Conclusion: We conclude that TP53genetic mutations are independent prognostic factors for tumor metastasis and recurrence and the genetic alternation of TP53 could be used for prediction of bladder tumorigenesis.

show abstract

“…Higher expression of TP53 mutation was observed in the high stage of bladder cancer or the MIBC, and lower expression of TP53 mutation in the Ta stage of bladder cancer or the NMIBC. The expression level of TP53 mutation was probably a critical diagnosed biomarker in advanced bladder cancer (Liao et al, 2021).…”

Section: Bladder Cancer Related Genes Were Confirmed By Literature Reviewmentioning

confidence: 99%

Identification of Prognostic Biomarkers for Bladder Cancer Based on DNA Methylation Profile

Zhang

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Background: DNA methylation is an important epigenetic modification, which plays an important role in regulating gene expression at the transcriptional level. In tumor research, it has been found that the change of DNA methylation leads to the abnormality of gene structure and function, which can provide early warning for tumorigenesis. Our study aims to explore the relationship between the occurrence and development of tumor and the level of DNA methylation. Moreover, this study will provide a set of prognostic biomarkers, which can more accurately predict the survival and health of patients after treatment.Methods: Datasets of bladder cancer patients and control samples were collected from TCGA database, differential analysis was employed to obtain genes with differential DNA methylation levels between tumor samples and normal samples. Then the protein-protein interaction network was constructed, and the potential tumor markers were further obtained by extracting Hub genes from subnet. Cox proportional hazard regression model and survival analysis were used to construct the prognostic model and screen out the prognostic markers of bladder cancer, so as to provide reference for tumor prognosis monitoring and improvement of treatment plan.Results: In this study, we found that DNA methylation was indeed related with the occurrence of bladder cancer. Genes with differential DNA methylation could serve as potential biomarkers for bladder cancer. Through univariate and multivariate Cox proportional hazard regression analysis, we concluded that FASLG and PRKCZ can be used as prognostic biomarkers for bladder cancer. Patients can be classified into high or low risk group by using this two-gene prognostic model. By detecting the methylation status of these genes, we can evaluate the survival of patients.Conclusion: The analysis in our study indicates that the methylation status of tumor-related genes can be used as prognostic biomarkers of bladder cancer.

show abstract

The potential diagnosis role of TP53 mutation in advanced bladder cancer: A meta‐analysis

Cited by 10 publications

References 45 publications

The prognostic role of p53 and its correlation with CDK9 in urothelial carcinoma

The prognostic role of p53 and its correlation with CDK9 in urothelial carcinoma

TP53 Mutation for Prediction of Tumor Recurrence and Metastasis in Bladder Cancer Patients

Identification of Prognostic Biomarkers for Bladder Cancer Based on DNA Methylation Profile

Contact Info

Product

Resources

About